欢迎光临源叶生物,登录 | 注册 |
当前位置: 首页 > 小分子化合物 > 小分子抑制剂 > Conoidin A

商品分类

浏览历史

T52231

Conoidin A

MedMol 98%
  • 英文名:
  • 2,3-BIS(BROMOMETHYL)QUINOXALINE 1,4-DIOXIDE
  • 别名:
  • 1,4-二氧代-2,3-二溴甲基喹啉;2,3-bis(broMoMethyl)-1-oxoquinoxalin-1-iuM-4(1H)-olate
  • CAS号:
  • 18080-67-6
  • 分子式:
  • C10H8Br2N2O2
  • 分子量:
  • 347.9907
  • 核磁/质谱:
品牌货号产品规格价格(RMB) 库存(上海) 北京 武汉 南京 数量计量单位 加入购物车...
MedMol T52231-100mg 98% ¥765.00元 10 0 0 0 EA 加入购物车
MedMol T52231-250mg 98% ¥1530.00元 预计交期:2-3天 0 0 0 EA 加入购物车
MedMol T52231-1g 98% ¥4250.00元 预计交期:2-3天 0 0 0 EA 加入购物车
大包装询价

提交您的电话号码并同意《个人信息授权与保护申明》,到货后将短信提示。
提交

产品介绍

参考文献

质检证书(COA)

摩尔浓度计算器

相关产品

  • 产品描述: Conoidin A is a cell permeable inhibitor of T. gondii enzyme peroxiredoxin II (TgPrxII) with nematicidal properties. Conoidin A covalently binds to the peroxidatic Cys47 of TgPrxII, irreversibly inhibiting its hyperperoxidation activity with an IC50 of 23 µM. Conoidin A also inhibits hyperoxidation of mammalian PrxI and PrxII (but not PrxIII). Conoidin A has antioxidant, neuroprotective effects and can be used for the research of ischaemic heart disease
  • 靶点: Toxoplasma
  • 体外研究: Peroxiredoxins are a widely conserved family of enzymes that function in antioxidant defense and signal transduction. And the changes in PrxII expression are associated with a variety of human diseases, including cancer.
    Conoidin A binds to the peroxidatic cysteine of TgPrxII, inhibiting its enzymatic activity in vitro. Conoidin A also shown to alkylate or crosslink catalytic cysteines of wild type AcePrx-1 in Ancylostoma ceylanicum and human PrxII and PrxIV with similar efficiency. But it is ineffective to mitochondrial hPrxIII.
    Conoidin A (5 µM) can inhibit the glucose oxidase-mediated hyperoxidation of mammalian peroxiredoxin I and II.
  • 体内研究: Conoidin A (intraperitoneal injection; 5 mg/kg; for three successive days before MI/R injury) blocks the effect of Luteolin (HY-N0162) on the ST‐segment elevation. Furthermore, an increase in the infarct size presented of the MI/R group can be reduced by Luteolin. But pre‐treatment with conoidin A abolishs the effect of Luteolin. Pre‐treatment with conoidin A also prevents Luteolin-reduced activities of CK‐MB, AST and LDH in vivo. Animal Model: Rat myocardial I/R model Dosage: 5 mg/kg Administration: Intraperitoneal injection; 5 mg/kg; for three successive days before MI/R injury Result: Significantly reversed the antioxidative effect of Luteolin.Impaired the protective effects of luteolin.
  • 参考文献:
    1. Jeralyn D Haraldsen, et al. IDENTIFICATION OF CONOIDIN A AS A COVALENT INHIBITOR OF PEROXIREDOXIN II. Org Biomol Chem. 2009;7:3040-3048.
    2. Gu Liu, et al. Optimisation of conoidin A, a peroxiredoxin inhibitor. ChemMedChem. 2010 Jan;5(1):41-5.
    3. Bo Wei, et al. Luteolin ameliorates rat myocardial ischaemia-reperfusion injury through activation of peroxiredoxin II. Br J Pharmacol
  • 溶解性: Soluble  in  DMSO
  • 保存条件: -20℃
  • 配置溶液浓度参考:
    1mg 5mg 10mg
    1 mM 2.874 ml 14.368 ml 28.736 ml
    5 mM 0.575 ml 2.874 ml 5.747 ml
    10 mM 0.287 ml 1.437 ml 2.874 ml
    50 mM 0.057 ml 0.287 ml 0.575 ml
  • 注意:部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。
输入产品批号:

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:


质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)


  • =
    *
    *


源叶所有产品仅用作科学研究,销售产品行为均适用于我司网上所列通用销售条款。